Zimbabwe has turned down a significant US healthcare agreement worth $367m (272 million pounds) spanning five years due to Washington's insistence on confidential biological samples.
This move came to light after a government memo dated December was disclosed, which showed President Emmerson Mnangagwa believed the arrangement was "unbalanced".
A government spokesman later stated that the United States was demanding access to health data for scientific study and commercial purposes while refused to guarantee the benefits from any future vaccines.
"We must now begin the challenging and unfortunate process of scaling back our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had donated over $1.9bn in health funding to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has called for further negotiations to secure a deal suitable to both sides so the nation's vital HIV programme can be sustained.
Wider Implications
This rejection follows a similar situation in neighbouring Kenya, where a high court blocked a related health funding agreement after legal challenges were filed about the security of citizens' health data.
After resuming the presidency last year, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
The agency had managed aid for the US government, but Trump claimed its expenditure was "inefficient" and his administration was pursuing government-to-government deals to enhance transparency and accountability.
According to reports, Sixteen nations in Africa have so far agreed to these new health pacts, constituting over $18.3bn in new funding.
Details of the Rejected Agreement
The funds for Zimbabwe was intended to supported "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this partnership might have yielded immense advantages for the people of Zimbabwe, especially the 1.2 million men, women and children currently receiving antiretroviral therapy through American-funded initiatives," Tremont added.
However, government spokesperson Nick Mangwana said the arrangement was "asymmetrical".
"Zimbabwe was being asked to provide its genetic material and health information over an extended period, with no equivalent guarantee of access to any scientific breakthroughs – such as new medicines or tests – that could result from that provided information," Mangwana explained.
"Effectively, our country would provide the basic resources for scientific discovery with no assurance that the end products would be accessible to our citizens if a new pandemic arise."
National Interest and Global Health
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were upending structures already set up through the international organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme created to manage future global health emergencies.
"This framework is designed to ensure that when a country provides its samples, the benefits – including medicines and cures – are distributed fairly, not commercialised exclusively by those with the resources to create them."
Zimbabwe's reservations regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We are open to ongoing discussions with our American counterparts on how future co-operation could be designed in a manner that honours the sovereignty and dignity of both nations."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the official position, but suggested that talks need to persist given that a large portion of the country's HIV programmes relied on international support.
"In cases where technical issues arise, including those relating to information security or agreement terms, these can often be resolved through technical clarification and mutually agreed protections," it said.
The halted deal underscores the complex challenges between accepting vital foreign assistance and protecting national sovereignty in an ever more data-driven world.